It now appears that genome-wide approaches using high-throughput sequencing technologies may provide this sorely needed perspective. In this issue of Cancer Cell, Riggi et al. (2014) demonstrate that EWS/FLI1 target genes can be parsed into two groups: (1) genes that are upregulated by EWS/FLI1 primarily through interacting with GGAA repeats present in satellite DNA within the genome and (2) genes that are downregulated by EWS/FLI1, whose regulatory regions contain canonical ETS-binding sites normally bound by ETS factors and that, in Ewing sarcoma, are displaced by the fusion. While some of these data echo previous findings from other investigative groups, the power of this current study is in its broad scope. By assessing EWS/ FLI1 occupancy at target gene regulatory sites along with co-factor occupancy and histone modification, broad trends are coming to light that can serve as a logical framework describing the EWS/ FLI1 target gene network.
Particularly intriguing is the further validation that EWS/FLI1 can use GGAA repeats as genomic response elements. This observation, first made by Gangwal et al. (2008) , prompted a fundamental mechanistic insight into the relative susceptibility of developing Ewing sarcoma. They posited that perhaps the very low incidence of Ewing sarcoma in the African population is due to differences in GGAAcontaining satellite DNA polymorphisms. The further development by Riggi et al. (2014) that, in binding GGAA repeats, EWS/FLI1 can then imbue them with enhancer-like qualities confirms at a molecular level another long-held belief that EWS/FLI1 is more than the sum of its parts. Functioning as a true chimera, EWS/FLI1 can do what neither normal EWS nor FLI1 can do.
While Riggi et al. (2014) provide an initial view into the broad EWS/FLI1 target gene landscape, further refinement can be anticipated. It seems likely that not all genes that are transcriptionally modulated by EWS/FLI1 promote oncogenesis in Ewing sarcoma. Distinguishing the pathophysiologically significant subset from the incidental targets will be a challenge. In this regard, fusion of large data sets generated by this and other parallel studies could help to further refine EWS/FLI1 target gene network models (Wang et al., 2012) .
Functionally inhibiting the EWS/FLI1 oncogenic program in a therapeutically meaningful way still seems like a daunting proposition. Simultaneous inhibition of the correct combination of target genes will likely be necessary to bring down this network. The hope that studies such as Riggi et al. (2014) inspire is that, in describing the system, it can now be strategically navigated. With the advent of such tools, the era of generating therapies to combat Ewing sarcoma based on educated guess and empiric intuition will hopefully draw to a close.
Plexiform neurofibromas are one of the most common tumors encountered in individuals with the neurofibromatosis type I (NF1) cancer predisposition syndrome. In this issue of Cancer Cell, Chen and colleagues define the cell of origin for murine Nf1 plexiform neurofibroma and leverage this finding to develop a platform for preclinical drug evaluation.
Neurofibromatosis type I (NF1) is one of the most common cancer predisposition syndromes, affecting 1 in 2,500 individuals worldwide (Lin and Gutmann, 2013) .
Among the diverse number of benign and malignant neoplasms observed in this condition, peripheral nerve sheath tumors (neurofibromas) are found in nearly all adults with NF1. One subtype of neurofibroma, the plexiform neurofibroma, is a particularly challenging tumor to manage. These extensive, highly vascular tumors typically involve multiple nerves or large segments of a nerve root, making complete surgical removal nearly impossible. In addition, they often affect adjacent structures in the body, leading to tissue compression (narrowed trachea or nerve impingement), bone erosion, or fatty replacement of muscle. Moreover, cytotoxic chemotherapy for plexiform neurofibromas has had modest effectiveness, and the use of radiation is limited by the risk of secondary malignant transformation.
These benign nerve sheath tumors can arise anywhere within the body, including the eye socket (orbit; Figure 1A ), neck ( Figure 1B ), spinal nerve roots ( Figure 1C ), subcutaneous tissue ( Figure 1D ), and extremities ( Figure 1E ). While histologically similar, their clinical behavior is influenced by the age of the patient and location of the tumor. First, the majority of plexiform neurofibromas grow most rapidly during the first decade of life. Second, while subcutaneous and orbital plexiform neurofibromas rarely trans-form into malignant peripheral nerve sheath tumors, there is a 10%-13% lifetime risk of malignant transformation for plexiform neurofibromas involving other body regions. Third, treatment with a biologically-targeted therapy (Imatinib) revealed greater responses in tumors of the neck and pelvis relative to those in other locations (Robertson et al., 2012) . Together, these clinical observations raise the intriguing possibility that plexiform neurofibromas arising in different areas are biologically distinct entities Cancer Cell and that the development of effective treatments will necessitate a deeper understanding of the molecular and cellular differences that underlie this innate heterogeneity.
As such, several different genetically engineered mouse models (GEMMs) of NF1-associated plexiform neurofibroma have been generated ( Figure 1F ). Relevant to the human condition, Nf1 GEMMs have emerged as critical experimental platforms to define the molecular and cellular pathogenesis of plexiform neurofibroma formation and growth. In this regard, these murine tumor models have been employed to demonstrate that plexiform neurofibromas can arise from some cell types (Schwann cell precursors, immature Schwann cells, and mature Schwann cells; Le et al., 2011; Zhu et al., 2002; Wu et al., 2008; Mayes et al., 2011) , but not others (neural crest stem cells; Joseph et al., 2008) . Similarly, both the penetrance and location of plexiform neurofibroma development is impacted by the age at which somatic Nf1 gene inactivation occurs, with rare tumors arising following acquired Nf1 loss in adult mice (Le et al., 2011) .
In this issue of Cancer Cell, Chen et al. (2014) determined that Nf1 murine spinal plexiform neurofibromas arise from a small population of PLP + Schwann cell precursors within the embryonic nerve root. Using embryonic dorsal root ganglion/nerve root neurosphere cells (DNSCs), they demonstrated that Nf1deficient DNSCs generate plexiform neurofibromas following injection into the sciatic nerves of naive immunocompromised mice. The development of tumors in mice without a germline Nf1 gene mutation or intact immune system further adds to the controversy over the absolute requirement for a supportive Nf1 +/À microenvironment in plexiform neurofibroma pathogenesis. In this regard, dependence on bone marrow-derived cells (mast cells and macrophages) and endothelial cells in the Nf1 +/À tumor microenvironment has been demonstrated in some models (Joseph et al., 2008; Le et al., 2011; Yang et al., 2008; Zhu et al., 2002) , but not in others (Mayes et al., 2011; Wu et al., 2008; Chen et al., 2014) . It is also possible that the ability to form tumors in wild-type mice reflects some degree of local injury at the site of the sciatic nerve injection sufficient to provide a supportive microenvironment for tumorigenesis (Ribeiro et al., 2013) .
Next, they employed inducible PLP-Cre ER mice to define the population of DNSCs most responsible for tumor formation, revealing that PLP + tumorigenic cells express the GAP43 Schwann cell precursor protein. In keeping with previous studies using Krox20-Cre (Zhu et al., 2002; Yang et al., 2008) or DHH-Cre (Mayes et al., 2011; Wu et al., 2008) mouse strains to generate plexiform neurofibromas, they found that Krox20 + and DHH + cells were contained within the PLP + DNSC population. Based on these fate mapping experiments, the authors conclude that PLP + , GAP43 + embryonic Schwann cell precursors represent the cellular origin for spinal plexiform neurofibromas.
Finally, because neurofibromin, the protein encoded by NF1, negatively regulates RAS/RAF/MEK activity relevant to murine Nf1 GEMM plexiform neurofibroma growth, Chen et al. (2014) utilized their Nf1-deficient DNSC sciatic nerve transplant model to perform proof-ofconcept studies using the selective MEK inhibitor PD0325901. They found that suppression of MEK activity reduced plexiform neurofibroma growth in vivo, further establishing this preclinical model as a tractable platform for future therapeutic drug discovery and evaluation. These encouraging results provide support for two ongoing human MEK inhibitor clinical studies on NF1-associated plexiform neurofibroma (www.clinicaltrials. gov; NCT01362803, NCT02096471).
Together with other Nf1 GEMM work, this study reveals that specific cell types during particular developmental windows are exquisitely vulnerable to the tumorigenic effects of somatic Nf1 gene inactivation. Similar to NF1-associated plexiform neurofibromas, not all cell types in the glial lineage are capable of generating NF1-associated low-grade brain tumors (optic gliomas). Somatic Nf1 gene loss must occur in neural stem cells originating within one specific germinal zone (third ventricle) during embryogenesis in order for mice to develop optic gliomas (Lee et al., 2012) . The requirement for somatic loss of Nf1 gene expression in a particular cell of origin during a restricted period of life may partly explain why not all people with NF1 develop particular tumors, why these tumors arise in specific locations, and why they may exhibit different growth properties or responses to biologically targeted therapies.
Beyond the important insights into pathogenesis that these experimental findings provide, they additionally offer exciting opportunities to develop Nf1 GEMMs that more accurately match specific subtypes of NF1-related tumors. It is important to recognize that the Nf1 GEMM plexiform neurofibroma model reported by Chen et al. (2014) most closely resembles the human paraspinal subtype ( Figure 1C ). As such, the growth control pathways deregulated in this subtype (e.g., MEK) and the relative contributions from the local microenvironment (e.g., athymic mice) may be most germane to this tumor subgroup. The creation of additional GEMMs that model other types of plexiform neurofibromas observed in people with NF1 will likely entail defining the cells of origin and vulnerable windows for each subtype using different regulatable Cre driver lines to enable somatic Nf1 loss in distinct cell types during defined periods of development ( Figure 1G) .
The availability of subtype-specific plexiform neurofibroma mouse strains would facilitate unbiased discovery efforts aimed at determining how these tumors are molecularly distinct from each other. In this manner, the unique biologies of these different subgroups and their respective mechanisms of growth regulation might be discerned. This knowledge coupled with the ability to establish xenograft models as executed by Chen et al. (2014) opens the door to the identification of drug therapies that might be particularly efficacious for each one of the varieties of plexiform neurofibroma. Furthermore, these future studies may lead to a greater appreciation of the factors that drive plexiform neurofibroma growth relevant to individual patient risk assessment. Continued progress in this area has the potential to allow for the development of prognostic strategies and treatments personalized to a given patient's tumor. Autophagy is an important cellular homeostasis pathway, but its role in cancer remains to be fully elucidated. In this issue of Cancer Cell, Hall and colleagues describe a TRPM3-dependent autophagy pathway that is selectively important for clear cell renal cell carcinoma and can be effectively inhibited.
Autophagy is a highly conserved homeostatic mechanism for the degradation and recycling of bulk cytoplasm, organelles, and long-lived proteins through the lysosomal machinery. Given its role in cellular homeostasis, it is not surprising that autophagy has been found to be deregulated in many human diseases, including cancer (Schneider and Cuervo, 2014). However, how autophagy contributes to cancer ontogenesis and progression has turned out to be more complex than expected. Overall, the emerging concept is that autophagy has both positive and negative effects, depending on the tumor stage. While functional autophagy prevents tumor initiation, its prosurvival effect may allow transformed cells to resist against adverse conditions. Consistently, several studies demonstrated that different autophagy-related genes play a central role in tumorigenesis by controlling tumor growth and/or tumor suppression (Guo et al., 2013; Takahashi et al., 2007) . Further, more recent evidence highlighted the existence of addi-tional roles besides autophagy regulation for autophagy-related factors. Indeed, the key pro-autophagic molecule Beclin 1 may also act in vacuolar protein sorting and the degradation of specific growth factor receptors (Funderburk et al., 2010) . More recently, a role for Beclin 1-mediated autophagy in the regulation of cancer cell growth induced by the epidermal growth factor receptor has also been demonstrated (Wei et al., 2013) . Such multiple roles for autophagy regulators may reflect the need for an integrated regulation of metabolic homeostasis.
One hypothesis about the impact of autophagy on cancer is that autophagydeficient cells accumulate malfunctioning proteins and organelles, leading to reactive oxygen species production, DNA damage, chromosomal instability, and activation of oncogenes. Another possibility is that autophagy plays a negative role in the control of cell proliferation. Indeed, mice with monoallelic deletion of Becn1 or Bif1 display a hyperproliferative phenotype (Qu et al., 2003; Takahashi et al., 2007) . On the other hand, in a cancer that develops in the absence of any recognizable autophagy defects, autophagy acts as an effective prosurvival process for cancer cells to sustain metabolic distress, react to prodeath stimuli, and circumvent nutrient deficiency. Along this line, autophagy represents a metabolic ''addiction'' for a successful cancer cell (Guo et al., 2013) .
As a consequence of this duality for cancer-related autophagy, the development of cancer therapies targeting autophagy is still very preliminary. Indeed, although the inconsiderate inhibition of autophagy may be beneficial for the treatment of well-established tumors, it is potentially dangerous to the patients' health. Therefore, generally disturbing the autophagy machinery or the autophagosome/autophagolysosome function should be avoided. In fact, it has been described that autophagy deficiency is responsible for tumorigenesis as well as defects in a plethora of other physiological processes (Schneider and Cuervo, 2014).
